Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

David Pyott Biography and Net Worth

Director of Alnylam Pharmaceuticals

Former Chair and Chief Executive Officer of Allergan; member of the Supervisory Board of Royal Philips in the Netherlands; Director of BioMarin Pharmaceutical and Pliant Therapeutics; former Lead Director of Avery Dennison Corporation.

What is David E. I. Pyott's net worth?: The estimated net worth of David E. I. Pyott is at least $33,305.04 as of June 24th, 2024. Mr. Pyott owns 136 shares of Alnylam Pharmaceuticals stock worth more than $33,305 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. Pyott may own. Learn More about David E. I. Pyott's net worth.
How do I contact David E. I. Pyott?: The corporate mailing address for Mr. Pyott and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on David E. I. Pyott's contact information.
Has David E. I. Pyott been buying or selling shares of Alnylam Pharmaceuticals?: David E. I. Pyott has not been actively trading shares of Alnylam Pharmaceuticals over the course of the past ninety days. Most recently, David E. I. Pyott sold 32,450 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a transaction totalling $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares of the company's stock, valued at $30,013.84. Learn More on David E. I. Pyott's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 8/20/2024.

David E. I. Pyott Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/24/2024	Sell	32,450	$220.69	$7,161,390.50	136
10/13/2016	Buy	27,900	$37.00	$1,032,300.00

David E. I. Pyott Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $244.89

$243.35

$248.90

50 Day Range

MA: $273.54

$232.27

$300.55

2 Week Range

Now: $244.89

$141.98

$304.39

Volume

525,884 shs

Average Volume

876,685 shs

Market Capitalization

$31.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Download Our Tesla Ebook For Free

From DTI | Ad